114 related articles for article (PubMed ID: 18819996)
1. Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
McCluskey AG; Boyd M; Pimlott SL; Babich JW; Gaze MN; Mairs RJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S28-35. PubMed ID: 18819996
[TBL] [Abstract][Full Text] [Related]
2. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
4. Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.
Kraal KC; Tytgat GA; van Eck-Smit BL; Kam B; Caron HN; van Noesel M
Pediatr Blood Cancer; 2015 Nov; 62(11):1886-91. PubMed ID: 25981988
[TBL] [Abstract][Full Text] [Related]
5. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill.
Boyd M; Mairs RJ; Mairs SC; Wilson L; Livingstone A; Cunningham SH; Brown MM; Quigg M; Keith WN
Oncogene; 2001 Nov; 20(53):7804-8. PubMed ID: 11753659
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.
Rae C; Tesson M; Babich JW; Boyd M; Mairs RJ
EJNMMI Res; 2013 Nov; 3(1):73. PubMed ID: 24219987
[TBL] [Abstract][Full Text] [Related]
8. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
McCluskey AG; Boyd M; Gaze MN; Mairs RJ
Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
[TBL] [Abstract][Full Text] [Related]
9. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
10. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
Mairs RJ; Ross SC; McCluskey AG; Boyd M
J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
Vaidyanathan G; McDougald D; Koumarianou E; Choi J; Hens M; Zalutsky MR
Nucl Med Biol; 2015 Aug; 42(8):673-84. PubMed ID: 25956997
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
13. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
14. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine.
Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE
Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418
[TBL] [Abstract][Full Text] [Related]
15. Dosimetry-based high-activity therapy with
Genolla J; Rodriguez T; Minguez P; Lopez-Almaraz R; Llorens V; Echebarria A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1567-1575. PubMed ID: 30838430
[TBL] [Abstract][Full Text] [Related]
16. A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE
J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115
[TBL] [Abstract][Full Text] [Related]
17. Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells.
Bayer M; Kuçi Z; Schömig E; Gründemann D; Dittmann H; Handgretinger R; Bruchelt G
Nucl Med Biol; 2009 Apr; 36(3):287-94. PubMed ID: 19324274
[TBL] [Abstract][Full Text] [Related]
18. Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines.
Meco D; Lasorella A; Riccardi A; Servidei T; Mastrangelo R; Riccardi R
Eur J Cancer; 1999 Aug; 35(8):1227-34. PubMed ID: 10615234
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.
Ferry I; Kolesnikov-Gauthier H; Oudoux A; Cougnenc O; Schleiermacher G; Michon J; Bogart E; Chastagner P; Proust S; Valteau-Couanet D; Defachelles AS
J Pediatr Hematol Oncol; 2018 Aug; 40(6):426-432. PubMed ID: 29642099
[TBL] [Abstract][Full Text] [Related]
20. Meta-[123I]iodobenzylguanidine is selectively radiotoxic to neuroblastoma cells at concentrations that spare cells of haematopoietic lineage.
He Y; Das B; Baruchel S; Kumar P; Wiebe L; Reilly RM
Nucl Med Commun; 2004 Nov; 25(11):1125-30. PubMed ID: 15577592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
